The Roswell Park Cancer Institute (RPCI) has been continuously recognized as a Comprehensive Cancer Center since the NCI designation of such centers in 1974 and is now requesting continued federal support for the next five years. A free-standing research, education and clinical cancer care Institute, RPCI occupies a 27 acre campus near downtown Buffalo and has expanded to nearly 1.6M gsf of clinical and research space, a 16% increase since the last review period. RPCI serves a population base of ~1.5M in Western New York where the RPCI tumor registry is recording more than 3,400 new cancer patients per year. RPCI has strong collaborations with the University of Buffalo and the Hauptman-Woodward Institute for Structural Biology, but is a fully independent entity with Dr. Donald Trump, CCSG PI and RPCI President/CEO, answering only to the RPCI Board of Directors. Since the last competitive renewal, the RPCI has grown significantly as demonstrated by: 1) the recruitment of over 100 new faculty clinicians and researchers of which 43 are new CCSG members;2) a 74% increase in total NCI funding and a 44% increase in total peer-reviewed funding;3) a 73% increase in accrual to investigator-initiated, interventional clinical trials and a 44% increase to accrual in all interventional trials;4) the addition of 4 new shared resources with an institutional investment of over $2.0 M and (5) the opening of a new, 177,000 gsf, state-of-the-art research building housing Program member laboratories and Shared Resources. With the growth in faculty has also come the recruitment of three Senior Leaders. In addition, a director for the newly created RPCI Office of Cancer Health Disparities Research has also been recruited. As part of the scientific growth within RPCI, a new disease-specific Research Program, the Prostate Program, has been added in this renewal bringing RPCI to a total of six Scientific Programs that also include Cancer Prevention &Population Sciences, Cell Stress &Biophysical Therapies, Genetics, Molecular Targets &Experimental Therapeutics and Tumor Immunology &Immunotherapy. With strong leadership and institutional commitment, RPCI will continue to focus on recruiting talented investigators to further expand research efforts targeting areas in genetics, investigational imaging and cancer health disparities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016056-34
Application #
7826851
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1997-06-16
Project End
2013-04-30
Budget Start
2010-05-18
Budget End
2011-04-30
Support Year
34
Fiscal Year
2010
Total Cost
$4,168,904
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Wintrob, Zachary A P; Hammel, Jeffrey P; Nimako, George K et al. (2017) Insulin use, hormone receptor status and hematopoietic cytokines? circulation in women with diabetes mellitus and breast cancer. Data Brief 11:382-390
Murphy, Maureen E; Liu, Song; Yao, Song et al. (2017) A functionally significant SNP in TP53 and breast cancer risk in African-American women. NPJ Breast Cancer 3:5
Liu, Song; Kumari, Sangeeta; Hu, Qiang et al. (2017) A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer. Elife 6:
Espinal, Allyson C; Buas, Matthew F; Wang, Dan et al. (2017) FOXA1 hypermethylation: link between parity and ER-negative breast cancer in African American women? Breast Cancer Res Treat 166:559-568
Danaher, Patrick; Warren, Sarah; Dennis, Lucas et al. (2017) Gene expression markers of Tumor Infiltrating Leukocytes. J Immunother Cancer 5:18
Oakley, Emily; Bellnier, David A; Hutson, Alan et al. (2017) Surface markers for guiding cylindrical diffuser fiber insertion in interstitial photodynamic therapy of head and neck cancer. Lasers Surg Med 49:599-608
Gage-Bouchard, Elizabeth A (2017) Social support, flexible resources, and health care navigation. Soc Sci Med 190:111-118
Moore, Kathleen N; Tritchler, David; Kaufman, Kenneth M et al. (2017) Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 147:396-401
Szender, J Brian; Papanicolau-Sengos, Antonios; Eng, Kevin H et al. (2017) NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. Gynecol Oncol 145:420-425
Ho, Christine M; McCarthy, Philip L; Wallace, Paul K et al. (2017) Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT. Blood Adv 1:1056-1066

Showing the most recent 10 out of 1391 publications